CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
Abatacept +1 moredrug
Likely dose
Abatacept 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03652961
NCT03652961Phase 4Completed
CompareCT.gov

Rheumatoid Arthritis Memory B Cells and Abatacept (RAMBA)

NYU Langone Health·interventional·Posted Aug 31, 2018·Updated Jul 3, 2024

In Brief

A Phase 4 clinical trial evaluating Abatacept and DMARDs for Rheumatoid Arthritis. Completed, enrolled 25 participants across 1 site.

Detailed Summary

Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment with Intravenous Abatacept Adults with Rheumatoid Arthritis who are Naive to Biologic Disease-Modifying Antirheumatic Drugs

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsDartmouth-Hitchcock Medical Center, Bristol-Myers Squibb

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedAug 31, 2018
Enrollment StartJun 2, 2019
Primary CompletionSep 27, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.8 years ago

Interventions

Abataceptdrug

Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.

DMARDsdrug

Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.